Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Pfizer Inc
Pfizer Inc And Renovis Inc
Pfizer Inc Products Inc
Pfizer Inc Pfizer Products Inc

Pfizer Inc patents (2016 archive)


Recent patent applications related to Pfizer Inc. Pfizer Inc is listed as an Agent/Assignee. Note: Pfizer Inc may have other listings under different names/spellings. We're not affiliated with Pfizer Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "P" | Pfizer Inc-related inventors


Pfizer Inc.

. . ... Pfizer Inc

Prostate-associated antigens and vaccine-based immunotherapy regimens

The present disclosure provides (a) isolated immunogenic paa polypeptides; (b) isolated nucleic acid molecules encoding immunogenic paa polypeptides; (c) vaccine compositions comprising an immunogenic paa polypeptide or an isolated nucleic acid molecule encoding an immunogenic paa polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.. . ... Pfizer Inc

Compositions and methods for treating intracerebral hemorrhage

The disclosure provides compositions and methods for treating or preventing intracerebral hemorrhage (ich) in a subject by administering a variant of fxa.. . ... Pfizer Inc

4-1bb binding molecules

The present disclosure provides isolated binding molecules that bind to human 4-1bb, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.. . ... Pfizer Inc

Novel pyridine pyrazinones as bet-family bromodomain inhibitors

Disclosed are novel pyridine pyrazinones or pharmaceutically acceptable salts thereof. Pharmaceutical compositions and the use of the compounds to treat diseases or disorders that are bet family bromodomain-dependent are also disclosed. ... Pfizer Inc

Dispensing device

A device for dispensing individual doses of powder from respective pockets of a disc-shaped carrier by outwardly rupturing a lidding foil by means of pressure on an opposite side surface, the device providing individual respective deaggregation flow paths for each pocket, split airstreams allowing improved entrainment of powder, a cam mechanism for outwardly rupturing the pockets, an indexing mechanism linked to the cam mechanism and a dose counter.. . ... Pfizer Inc

Pfizer Inc.

. . ... Pfizer Inc

Pfizer Inc.

. . ... Pfizer Inc

Pfizer Inc.

. . ... Pfizer Inc

Neisseria meningitidis composition and methods thereof

In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to seq id no: 68. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated orf2086 polypeptide from neisseria meningitidis serogroup b, and at least one conjugated capsular saccharide from a meningococcal. ... Pfizer Inc

Process for annealing amorphous atorvastatin

Processes for annealing amorphous atorvastatin is described. Pharmaceutical compositions and formulations containing annealed amorphous atorvastatin are also described.. ... Pfizer Inc

2-thiopyrimidinones

Myeloperoxidase inhibitor, pharmaceutical compositions containing the inhibitor and the use of the inhibitor to treat, for example, cardiovascular conditions.. . ... Pfizer Inc

Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof

The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (cp) from streptococcus agalactiae, commonly referred to as group b streptococcus (gbs), and a carrier protein, wherein the cp is selected from the group consisting of serotypes ia, ib, ii, iii, iv, v, vi, vii, viii, and ix, and wherein the cp has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. ... Pfizer Inc

Streptococcus pneumoniae capsular polysaccharides and conjugates thereof

The invention relates to isolated streptococcus pneumoniae serotype 15b capsular polysaccharide and processes for their preparation. The invention also relates to immunogenic conjugates comprising streptococcus pneumoniae serotype 15b capsular polysaccharide covalently linked to a carrier protein, processes for their preparation and immunogenic compositions comprising them.. ... Pfizer Inc

11/10/16 / #20160324948

Streptococcus pneumoniae capsular polysaccharides and conjugates thereof

The invention relates to activated streptococcus pneumoniae serotype 10a, 22f or 33f polysaccharides and processes for their preparation. The invention also relates to immunogenic conjugates comprising streptococcus pneumoniae serotype 10a, 22f or 33f polysaccharides covalently linked to a carrier protein, processes for their preparation and immunogenic compositions and vaccines comprising them.. ... Pfizer Inc

10/27/16 / #the present disclosure provides a compound of formula i:

Pfizer Inc.

. . ... Pfizer Inc

10/20/16 / #20160304469

2-thiopyrimidinones

Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.. . ... Pfizer Inc

10/20/16 / #20160303125

Diacylglycerol acyltransferase 2 inhibitors

Compounds of formula i that inhibit the activity of the diacylglycerol acyltransferase 2 (dgat2) and their uses in the treatment of diseases linked thereto in animals are described herein.. . ... Pfizer Inc

10/13/16 / #20160297885

Therapeutic antibodies and their uses

The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to bcma (b-cell maturation antigen) and/or cd3 (cluster of differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the bcma antibodies, compositions comprising the bcma antibodies, and methods of using the bcma antibodies and their conjugates for treating conditions associated with cells expressing bcma (e.g., cancer or autoimmune disease). ... Pfizer Inc

10/13/16 / #20160297884

Chimeric antigen receptors targeting b-cell maturation antigen

The invention provides cars (cars) that specifically bind to bcma (b-cell maturation antigen). The invention further relates to engineered immune cells comprising such cars, car-encoding nucleic acids, and methods of making such cars, engineered immune cells, and nucleic acids. ... Pfizer Inc

09/22/16 / #the present invention is directed to novel bifunctional cti-cti and cbi-cti dimers of the formula:

Pfizer Inc.

. . ... Pfizer Inc

09/22/16 / #the invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula i:

Pfizer Inc.

. . ... Pfizer Inc

09/15/16 / #20160263097

Apixaban liquid formulations

Apixaban liquid formulation is provided. Also provided is a method of administering an apixaban liquid formulation.. ... Pfizer Inc

09/01/16 / #the present invention relates to intermediates of formula i

Pfizer Inc.

. . ... Pfizer Inc

08/25/16 / #compounds of the general formula (i):

Pfizer Inc.

. . ... Pfizer Inc

08/25/16 / #20160243101

Apixaban formulations

Compositions comprising crystalline apixaban particles having a d90 equal to or less than 89 μm, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.. . ... Pfizer Inc

08/18/16 / #20160235829

Vectors for expression of prostate-associated antigens

The present disclosure provides (a) vectors comprising a multi-antigen construct encoding two, three, or more immunogenic paa polypeptides; (b) compositions comprising the vectors, (c) methods relating to uses of the vectors and compositions for eliciting an immune response or for treating prostate cancers.. . ... Pfizer Inc

08/11/16 / #20160229847

Novel bicyclic pyridinones as gamma-secretase modulators

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of formula ii as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.. ... Pfizer Inc

08/11/16 / #20160229842

Process for the preparation of voriconazole and analogues thereof

The present invention provides a process for preparing a compound of formula: (formula xi and xii) (xi) (xii) wherein x, y, z, a, b and e are as defined herein, by reacting a compound of formula: (formula xiii) (xiii) with a compound of formula: (formula xiv and xv) (xiv) (xv) respectively, in the presence of a transition metal catalyst, a ligand suitable for use with 15 the catalyst and a reducing agent. The invention also provides novel intermediates.. ... Pfizer Inc

08/04/16 / #the present invention relates to compounds of formula i

Pfizer Inc.

. . ... Pfizer Inc

08/04/16 / #compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of formula i

Pfizer Inc.

. . ... Pfizer Inc

08/04/16 / #20160220557

Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris

The present invention relates to methods of treating and/or preventing acne in patients comprising the step of administering to patients in need of such treatment a therapeutically effective amount of an acc inhibitor or a pharmaceutically acceptable salt thereof.. . ... Pfizer Inc

07/21/16 / #20160207991

Therapeutic antibody

The present invention relates to antibodies that bind brain-derived neurotrophic factor (bdnf). The invention further relates to nucleic acid sequences coding for such antibodies. ... Pfizer Inc

07/21/16 / #20160207953

Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of asgpr

Compounds of formula (a) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (asgpr) targeting agents.. . ... Pfizer Inc

07/21/16 / #20160206608

Crizotinib for use in the treatment of cancer

The present invention relates to the use of ros kinase inhibitors for treating abnormal cell growth in mammals. In particular, the invention provides methods of treating mammals suffering from cancer mediated by at least one genetically altered ros. ... Pfizer Inc

07/14/16 / #the present invention provides, in part, compounds of formula i:

Pfizer Inc.

. . ... Pfizer Inc

07/14/16 / #20160199409

Oral delivery product

This invention provides a nutritional supplement composition which is a vitamin mint that can be taken anytime or anywhere without water or other liquid which is usually required for swallowing a tablet. The present invention is a nutritional supplement composition which is a convenient, flavorful and enjoyable vitamin mint which can be ingested without water.. ... Pfizer Inc

07/07/16 / #20160194662

Recombinant virus-like particles encoded by multi-gene vector

The invention describes novel virus-like particles for use as vaccines, diagnostic tools and r&d tools based on recombinant dna and cell cultivation techniques for production. The recombinant virus-like particles of the invention are assembled by polypeptide chains that incorporate several, in particular two or more, different epitopes which are selected either (a) from different viral strains of the same virus and/or (b) from different serotypes of the same virus and/or (c) from different viral strains specific for different hosts. ... Pfizer Inc

06/02/16 / #the present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of formula i,

Pfizer Inc.

. . ... Pfizer Inc

06/02/16 / #20160152734

Treatment with anti-pcsk9 antibodies

The present invention concerns dosages for the treatment of human patients susceptible to or diagnosed with a disorder characterized by marked elevations of low density lipoprotein particles in the plasma with a pcsk9 antagonist antiboyd alone or in combination with a statin.. . ... Pfizer Inc

06/02/16 / #20160152722

Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer

Methods for treating cancer in a patient in need thereof, with a therapeutically effective amount of an anti-4-1bb antibody in combination with a therapeutically effective amount of an adcc-inducing antibody, are disclosed.. . ... Pfizer Inc

06/02/16 / #20160152713

Antibodies to cd40

The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to cd40, preferably human cd40, and that function as cd40 agonists. The invention also relates to human anti-cd40 antibodies and antigen-binding portions thereof. ... Pfizer Inc

06/02/16 / #20160151280

Enhanced stability of novel liquid compositions

The present invention relates to compositions of pharmaceutical agents in combination with additional pharmaceutical agents in a mixture of polyethylene glycol, polyvinylpyrrolidone, and propylene glycol and a process of making the compositions.. . ... Pfizer Inc

05/19/16 / #the present invention relates to methods of delaying progression to end stage renal disease (esrd) in patients comprising administration of 1-(2-ethoxyethyl)-5-(ethyl(methyl)amino)-7-((4-methylpyridin-2-yl)amino)-n-(methylsulfonyl)-1h-pyrazolo[4,3-d]pyrimidine-3-carboxamide. the present invention also includes administration of pharmaceutical compositions for delaying progression to esrd.

Pfizer Inc.

. . ... Pfizer Inc

05/19/16 / #20160135986

Cold therapy device

The present invention is directed to a device for absorbing heat from a body. More particularly, the invention pertains to an improved device which utilizes a gel material comprising liquids and solids to absorb, over an extended period of time, heat from a body. ... Pfizer Inc

05/12/16 / #the present invention relates to a compound of the formula i

Pfizer, Inc.

. . ... Pfizer Inc

05/05/16 / #20160122799

Fecal recovery assay

The fecal recovery assay of this invention accurately quantifies the number of viable bb12 colonies in the gastrointestinal tract of humans and animals. This bb12 culture method is highly selective for isolating bb12 colonies from human stool. ... Pfizer Inc

04/28/16 / #20160115178

Solid forms of a macrocyclic kinase inhibitor

This invention relates to crystalline solvates of (10r)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2h-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile, useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to pharmaceutical compositions comprising such crystalline solvates, and to methods of using such solvates and compositions in the treatment of abnormal cell growth in mammals, especially humans.. ... Pfizer Inc

03/31/16 / #20160090381

Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof

The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating rorγ activity and/or reducing the amount of il-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.. . ... Pfizer Inc

03/03/16 / #20160060343

Cancer treatment

The present invention relates to methods of treating cancer, such as melanoma, by administering a ctla4 antagonist to a subject with a serum c-reactive protein (crp) concentration that is less than or equal to some amount. The invention further relates to methods of treating cancer by determining the level of serum crp concentration in a subject, and then administering a ctla4 antagonist if the crp concentration is less than or equal to a certain amount. ... Pfizer Inc

03/03/16 / #20160058768

Substituted amide compounds

The present invention is directed at substituted amide compounds, pharmaceutical compositions containing such compounds and the use of such compounds to reduce plasma lipid levels, such as ldl-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by high levels of ldl-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.. . ... Pfizer Inc

02/25/16 / #a compound having the structure:

Pfizer Inc.

. . ... Pfizer Inc

02/18/16 / #20160046597

Rorc2 inhibitors and methods of use thereof

The present invention provides compounds, pharmaceutical compositions, methods of inhibiting rorγ activity and/or reducing the amount of il-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.. . ... Pfizer Inc

02/18/16 / #20160045508

Pyrrolo[2,3-d]pyrimidine derivatives

Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as janus kinase (jak) inhibitors, pharmaceutical compositions containing them, and therapeutic uses thereof.. . ... Pfizer Inc

02/11/16 / #the present invention is directed to compounds of formula i:

Pfizer Inc.

. . ... Pfizer Inc

02/11/16 / #20160039914

Humanized antibodies specific for staphylococcal enterotoxin b

Humanized antibodies to seb, fragments thereof, and compositions comprising such are provided. Therapies for staphylococcal infections and diseases are also provided. ... Pfizer Inc

02/04/16 / #20160030543

Neisseria meningitidis compositions and methods thereof

In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to seq id no: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated orf2086 polypeptide from neisseria meningitidis serogroup b, and at least one conjugated capsular saccharide from a meningococcal serogroup.. ... Pfizer Inc

01/28/16 / #compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of formula i

Pfizer Inc.

. . ... Pfizer Inc

01/28/16 / #20160024540

Process and intermediates for the preparation of pregabalin

The invention provides processes for the manufacture of a compound of formula (ia). The invention further provides improved methods for the conversion of the compound of formula (ia) into pregabalin.. ... Pfizer Inc

01/28/16 / #20160022626

Spliceostatin analogs and methods for their preparation

The present invention is directed to novel cytotoxic spliceostatin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.. . ... Pfizer Inc

01/21/16 / #the present invention provides, in part, compounds of formula i:

Pfizer Inc.

. . ... Pfizer Inc

01/21/16 / #20160017006

Immunogenic fusion polypeptides

In one aspect, the invention relates to an isolated polypeptide including the amino acid sequence of a carrier polypeptide and the amino acid sequence of an orf2086 polypeptide. In another aspect, the invention relates to an immunogenic conjugate including orf2086 polypeptide and a carrier polypeptide. ... Pfizer Inc

01/21/16 / #20160016940

Indole and indazole compounds that activate ampk

The present invention relates to indole and indazole compounds of formula (i) that activate 5′ adenosine monophosphate-activated protein kinase (ampk). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of ampk.. ... Pfizer Inc

01/14/16 / #20160008485

Engineered antibody constant regions for site-specific conjugation and methods and uses therefor

The present invention is directed to antibodies, and antigen-binding portions thereof, engineered to introduce amino acids for site-specific conjugation. The invention relates to engineered antibody constant region (fc, cγ, cκ, and cλ) polypeptides, and portions thereof, and antibodies comprising the polypeptides. ... Pfizer Inc

01/07/16 / #the present invention provides compounds of formula i,

Pfizer Inc.

. . ... Pfizer Inc

01/07/16 / #20160002361

Saccharides and uses thereof

The invention relates to novel saccharides and uses thereof. In one aspect, the invention relates to a saccharide having a legionaminic acid moiety, a n-acetylgalactosamine moiety, a galactose moiety, and a glucose moiety. ... Pfizer Inc

01/07/16 / #20160002357

Bispecific heterodimeric diabodies and uses thereof

Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the p-cadherin tumor cell associated antigen and the cd3 t cell antigen.. ... Pfizer Inc

01/07/16 / #20160002223

Solid forms of a selective cdk4/6 inhibitor

This invention relates to the crystalline free base of acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8h-pyrido[2,3-d]pyrimidin-7-one, formula (1) having improved properties, to pharmaceutical compositions and dosage forms comprising the free base, and to methods for making and using such compounds, compositions and dosage forms in the treatment of cell proliferative diseases, such as cancer.. . ... Pfizer Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Pfizer Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Pfizer Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###